Publications by authors named "G F Melloni"
Chronic obstructive pulmonary disease (COPD) is among the most relevant comorbidity associated with lung cancer. The advent of innovative triple treatment approaches for COPD has significantly improved patients' quality of life and outcomes. Few data are available regarding the impact of triple inhaler therapy on patients featuring COPD and lung cancer.
View Article and Find Full Text PDFArticle Synopsis
- Pleural mesothelioma (PM) is a rare cancer closely associated with asbestos exposure, currently lacking effective treatment options, leading to a poor prognosis.
- The study explores using mesenchymal stromal cells (MSCs) to deliver the chemotherapy drug Paclitaxel (PTX) directly to the pleural cavity, aiming to enhance drug concentration at the tumor site while reducing side effects.
- The PACLIMES trial assesses the safety and toxicity of this local PTX administration in patients eligible for surgery, with a goal to identify the effective dose for future studies and evaluate its anti-tumor effects.
Recent studies have emphasized the critical role of alteration in cellular plasticity in the development of fibrotic disorders, particularly pulmonary fibrosis, prompting further investigation into molecular mechanisms and therapeutic approaches. In this context, Precision Cut Lung Slices (PCLSs) emerge as a valuable ex vivo research tool. The process of PCLSs generation preserves most features of the naïve lung tissue, such as its architecture and complex cellular composition.
View Article and Find Full Text PDFArticle Synopsis
- Clonal hematopoiesis of indeterminate potential (CHIP) is linked to a higher risk of cardiovascular (CV) disease in general populations, but its impact on patients with existing CV conditions in clinical trials was unclear.
- A study of 63,700 patients from five randomized CV therapy trials found that while CHIP+ patients had a 30% higher risk of a first myocardial infarction (heart attack), their risk for recurrent heart attacks showed no significant increase.
- The research also indicated that CHIP does not significantly affect the effectiveness of standard CV treatments, suggesting that both CHIP+ and CHIP- patients benefit similarly from these therapies.
Article Synopsis
- A clinical risk model was created to identify individuals at higher risk for developing new-onset diabetes, helping to target those who would benefit most from weight loss medication.
- The study analyzed data from over 21,000 patients without type 2 diabetes, assessing 27 risk factors and ultimately identifying five key predictors linked to new-onset diabetes.
- The model demonstrated strong accuracy and differentiation in predicting risk levels and showed varying degrees of benefit from weight-loss therapy based on an individual's risk status.